YieldMax NVDA Option Income Strategy ETF vs Smith & Nephew plc — how do they compare? YieldMax NVDA Option Income Strategy ETF trades at $12.57 (market cap $1.45B), while Smith & Nephew plc trades at $27.24 (market cap $11.10B). The key difference: Smith & Nephew plc is far larger — about 7.7× YieldMax NVDA Option Income Strategy ETF's market cap, and Smith & Nephew plc pays a 2.95% dividend while YieldMax NVDA Option Income Strategy ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold YieldMax NVDA Option Income Strategy ETF for 43 Days and Smith & Nephew plc for 121 Days on average.
| NVDY | SNN | |
|---|---|---|
Market Cap | $1.45B | $11.10B |
Volume | 1,943,739 | 1,051,703 |
Sector | Income / Options Overlay | Health |
52-Week High | $17.21 | $37.17 |
52-Week Low | $11.58 | $26.42 |
Typical Hold Time | 43 Days | 121 Days |
Enterprise Value | — | $14.13B |
Dividend Yield | — | 2.95% |
Signals from Pluang's Aura AI — not financial advice
NVDY, the YieldMax NVDA Option Income Strategy ETF, trades at $12.62, down 3.0% today, amid a bearish technical signal. The fund generates income via options on NVIDIA stock, with recent weekly dividends averaging around $0.10. However, technical indicators show selling pressure, with moving averages and ADX signaling bearish momentum, while oscillators remain neutral. Recent news highlights concerns over NAV erosion and capped upside despite high distribution yields.
The outlook is cautious due to structural limitations on capital appreciation and reliance on NVIDIA's volatility for income. Risks include potential NAV decay from the options strategy and sensitivity to changes in implied volatility. Analyst sentiment is neutral to bearish, with downgrades citing diminished income potential. Investors seeking NVIDIA exposure may find direct ownership more favorable for growth.
Smith+Nephew (SNN) trades at $26.96, near its 52-week low, with bearish technical signals despite recent earnings beats. The company shows strong fundamentals with revenue growth to $6.16B in 2025 and improving profit margins of 10.08%. Recent product launches in trauma care and surgical robotics highlight innovation, but analyst sentiment remains cautious with 65% hold ratings.
Investment outlook is mixed: solid fundamentals and product pipeline offer upside, but technical weakness and analyst skepticism pose near-term risks. Key catalysts include execution on new product adoption and margin expansion, while risks involve competitive pressures and leadership transitions following the CFO's departure.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →